Investors & News Featured Aug 31, 2021 KalGene Pharmaceuticals, Inc. announces a new peer-review publication demonstrating the efficacy of KG207 in clearing toxic oligomer species of amyloid beta in translational imaging studies Aug 31, 2021 Read More → Aug 31, 2021 Aug 10, 2021 Kalgene Pharmaceuticals Inc., an Alzheimer’s focused company using a next generation engineered drug candidate, has appointed new leadership. Aug 10, 2021 Read More → Aug 10, 2021
